BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 29769294)

  • 1. Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease.
    Caron M; Hoa S; Hudson M; Schwartzman K; Steele R
    Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29769294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease.
    Moore OA; Proudman SM; Goh N; Corte TJ; Rouse H; Hennessy O; Morrisroe K; Thakkar V; Sahhar J; Roddy J; Youssef P; Gabbay E; Nash P; Zochling J; Stevens W; Nikpour M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S111-6. PubMed ID: 26243401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis.
    Showalter K; Hoffmann A; Rouleau G; Aaby D; Lee J; Richardson C; Dematte J; Agrawal R; Chang RW; Hinchcliff M
    J Rheumatol; 2018 Nov; 45(11):1572-1576. PubMed ID: 30275265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
    Goh NS; Hoyles RK; Denton CP; Hansell DM; Renzoni EA; Maher TM; Nicholson AG; Wells AU
    Arthritis Rheumatol; 2017 Aug; 69(8):1670-1678. PubMed ID: 28426895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brief Report: Pulmonary Function Tests: High Rate of False-Negative Results in the Early Detection and Screening of Scleroderma-Related Interstitial Lung Disease.
    Suliman YA; Dobrota R; Huscher D; Nguyen-Kim TD; Maurer B; Jordan S; Speich R; Frauenfelder T; Distler O
    Arthritis Rheumatol; 2015 Dec; 67(12):3256-61. PubMed ID: 26316389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease.
    Le Gouellec N; Duhamel A; Perez T; Hachulla AL; Sobanski V; Faivre JB; Morell-Dubois S; Lambert M; Hatron PY; Hachulla E; Béhal H; Matran R; Launay D; Remy-Jardin M
    PLoS One; 2017; 12(8):e0181692. PubMed ID: 28763468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis.
    Hoffmann-Vold AM; Aaløkken TM; Lund MB; Garen T; Midtvedt Ø; Brunborg C; Gran JT; Molberg Ø
    Arthritis Rheumatol; 2015 May; 67(8):2205-12. PubMed ID: 25916462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of interstitial lung disease in systemic sclerosis through partitioning of lung transfer for carbon monoxide.
    Pernot J; Puzenat E; Magy-Bertrand N; Manzoni P; Gondouin A; Bourdin H; Simon-Rigaud ML; Regnard J; Degano B
    Respiration; 2012; 84(6):461-8. PubMed ID: 22301769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KL6 and IL-18 levels are negatively correlated with respiratory function tests and ILD extent assessed on HRCT in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).
    Sieiro Santos C; Antolín SC; Lorenzo JC; Garay CL; Morales CM; de Miguel EB; Guerrero MR; Herránz LS; Álvarez ED
    Semin Arthritis Rheum; 2024 Apr; 65():152366. PubMed ID: 38290372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emphysematous change with scleroderma-associated interstitial lung disease: the potential contribution of vasculopathy?
    Yamakawa H; Takemura T; Iwasawa T; Yamanaka Y; Ikeda S; Sekine A; Kitamura H; Baba T; Iso S; Okudela K; Kuwano K; Ogura T
    BMC Pulm Med; 2018 Jan; 18(1):25. PubMed ID: 29382307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis.
    Guarnieri G; Zanatta E; Mason P; Scarpa MC; Pigatto E; Maestrelli P; Cozzi F
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S80-6. PubMed ID: 25897784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
    Tashkin DP; Volkmann ER; Tseng CH; Kim HJ; Goldin J; Clements P; Furst D; Khanna D; Kleerup E; Roth MD; Elashoff R
    Ann Rheum Dis; 2016 Feb; 75(2):374-81. PubMed ID: 25452309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Pulmonary Fibrosis and Emphysema in Scleroderma-Related Lung Disease Has a Major Confounding Effect on Lung Physiology and Screening for Pulmonary Hypertension.
    Antoniou KM; Margaritopoulos GA; Goh NS; Karagiannis K; Desai SR; Nicholson AG; Siafakas NM; Coghlan JG; Denton CP; Hansell DM; Wells AU
    Arthritis Rheumatol; 2016 Apr; 68(4):1004-12. PubMed ID: 26636545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
    Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
    Wu W; Jordan S; Becker MO; Dobrota R; Maurer B; Fretheim H; Ye S; Siegert E; Allanore Y; Hoffmann-Vold AM; Distler O
    Ann Rheum Dis; 2018 Sep; 77(9):1326-1332. PubMed ID: 29875097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease in systemic sclerosis.
    Bussone G; Mouthon L
    Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
    Panopoulos ST; Bournia VK; Trakada G; Giavri I; Kostopoulos C; Sfikakis PP
    Lung; 2013 Oct; 191(5):483-9. PubMed ID: 23925736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience.
    Chartrand S; Lee JS; Swigris JJ; Stanchev L; Fischer A
    Lung; 2019 Dec; 197(6):709-713. PubMed ID: 31583453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.